

LGC Science Ireland Limited

**Directors' Report and Financial Statements
for the Year Ended 31 March 2025**

LGC Science Ireland Limited

Contents

Page	
Company Information	2
Directors' Report	3 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7 - 9
Profit and Loss Account and Other Comprehensive Income	10
Statement of Changes in Equity	11
Balance Sheet	12
Notes to the Financial Statements	13 - 19

LGC Science Ireland Limited

Company Information

Directors	Lucas-Caspar Schwinner-Strachwitz (UK) (appointed 15 th April 2025) Donal Tabb
Company secretary	Wilton Secretarial Limited
Registered number	668590
Registered office	6th Floor 2 Grand Canal Square Dublin 2
Independent auditors	KPMG 85 South Mall Cork T12 A3XN
Solicitors	William Fry 2 Grand Canal Square Dublin 2

LGC Science Ireland Limited

Directors' Report for the Year Ended 31 March 2025

The directors present their annual report and the audited financial statements for the year ended 31 March 2025.

Principal activities and review of the business

The Company is an intermediate investment holding company and is a subsidiary of LGC (Holdings) Limited, a company incorporated in the Republic of Ireland.

Results for the year

The Profit and Loss Account and Other Comprehensive Income for the year ended 31 March 2025, the Statement of Changes in Equity and the Balance Sheet as at that date are set out on pages 10 to 12. The loss for the year before taxation amounted to (€4,498,492) (2024: profit of €1,055,425). After taxation impact of €Nil (2024: €Nil), the loss for the year of (€4,498,492) (2024: profit of €1,055,425) is transferred to profit and loss reserves.

Dividends

The directors of the Company did not propose, declare or pay any dividends during the year ended 31 March 2025 (2024: €Nil).

Directors

The directors who served during the year were:
Lucas-Caspar Schwinner-Strachwitz (Appointed 15th April 2025)
Donal Tabb
Michael Gilroy (Resigned 12th April 2025)
Euan O'Sullivan (Resigned 31st January 2025)

The secretary who served throughout the financial year was Wilton Secretarial Limited.

Principal risks and uncertainties

The Company is dependent on the ongoing profitability of its subsidiaries. The principal business risks and uncertainties faced by the Company relate to changes in market or regulatory conditions that impact the subsidiaries' business, as follows:

- Inability to meet regulatory quality standards applicable to the manufacturing and quality processes and the associated risk of product recalls.
- Pending and potential future intellectual property litigation, product liability claims and other litigation.
- Healthcare costs containment pressures and consolidation in the healthcare industry.
- Intensifying competition among medical device companies and rapid technological changes in the medical devices industry.
- Changes in international economic conditions, including foreign currency and interest rate fluctuations.

Future developments

The Company intends to continue to manage its existing business and to act as an intermediate investment holding company.

LGC Science Ireland Limited

Directors and secretary and their interests

The directors and secretary who held office at 31 March 2025 had no other interests in the shares in, or debentures or loan stock of, the Company or group companies and in options to acquire shares in the Company or group companies

Going concern

The Company's business activities, together with the factors likely to affect its future development, its financial position, and the principal risks and uncertainties likely to impact the Company are set out above.

The Company has net current assets of €2.9 million (2024: €9.7 million net current assets) and net assets of €77.2 million (2024: €81.8 million) at 31 March 2025. The directors are satisfied that the Company has sufficient funding to meet any short-term obligations which may arise during the period of 12 months from the date of approval of the financial statements. Further, the Company has obtained a letter of support from LGC Science Group Holdings Limited, the Company's intermediate parent company. The directors have confirmed the ability of LGC Science Group Holdings Limited to provide this support for a period of 12 months from the date of approval of these financial statements.

Accordingly, the directors have determined that it is appropriate, based on the above facts and circumstances, to adopt the going concern basis of accounting in preparing these financial statements.

Post balance sheet events

LGC Science Ireland disposed of its share in Innovapeak Limited in July 2025. The agreed sale price was a reduction in the prior value of the investment and this impairment is reflected in this set of accounts for year ended 31st March 2025.

Accounting records

The measures taken by the directors to ensure compliance with the requirements of Sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records, are the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The Company's accounting records are maintained at its subsidiary company's registered office at Technopath Life Science Park, Fort Henry, Ballina, Co. Tipperary.

Disclosure of information to the auditors

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information, being information needed by the auditor in connection with preparing its report, of which the auditor is unaware. Having made inquiries of fellow directors and the Company's auditor, each director has taken all the steps that they are obliged to take as a director in order to make them aware of any relevant audit information and to establish that the auditor is aware of that information.

Auditors

The auditors, KPMG, will continue in office in accordance with section 383(2) of the Companies Act 2014.

LGC Science Ireland Limited

On behalf of the board

Signed by:

Donal Tabb

.....
F859F0968D50462...
Donal Tabb

DocuSigned by:

Caspar Schwinner

.....
E0DFB12A4E9B484...
Lucas-Caspar Schwinner-Strachwitz

LGC Science Ireland Limited

Statement of Directors' Responsibilities in respect of the directors' report and the financial statements for the Year Ended 31 March 2025

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company and of its profit or loss for that year.

In preparing the financial statements, the directors are required to:


- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the Company and enable them to ensure that the financial statements are prepared in accordance with the applicable accounting framework and comply with the provisions of the Companies Act 2014. They are responsible for such internal controls as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities. The directors are also responsible for preparing a directors' report that complies with the requirements of the Companies Act 2014.

On behalf of the board

Signed by:

.....
F859F0D68D50462...
Donal Tabb

DocuSigned by:

.....
E6DFB12A4E9B484...
Lucas-Caspar Schwinner-Strachwitz



KPMG

Audit
85 South Mall
Cork
T12 A3XN
Ireland

Independent auditor's report to the members of LGC Science Ireland Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of LGC Science Ireland Limited ('the Company') for the year ended 31 March 2025 set out on pages 10 to 19, which comprise the Profit and Loss Account and Other Comprehensive Income, Statement of Changes in Equity, Balance Sheet, and related notes, including the summary of significant accounting policies set out in note 2.

The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland issued in the United Kingdom by the Financial Reporting Council.

In our opinion:

- the financial statements give a true and fair view of the assets, liabilities and financial position of the Company as at 31 March 2025 and of its loss for the year then ended;
- the financial statements have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- the financial statements have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.



Independent auditor's report to the members of LGC Science Ireland Limited (continued)

Report on the audit of the financial statements (continued)

Other information

The directors are responsible for the other information presented in the Annual Report together with the financial statements. The other information comprises the information included in the directors' report. The financial statements and our auditor's report thereon do not comprise part of the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except as explicitly stated below, any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether, based on our financial statements audit work, the information therein is materially misstated or inconsistent with the financial statements or our audit knowledge. Based solely on that work we have not identified material misstatements in the other information.

Based solely on our work on the other information undertaken during the course of the audit, we report that:

- we have not identified material misstatements in the directors' report;
- in our opinion, the information given in the directors' report is consistent with the financial statements; and
- in our opinion, those parts of the directors' report specified for our review, which does not include sustainability reporting when required by Part 28 of the Companies Act 2014, have been prepared in accordance with the Companies Act 2014.

Our opinions on other matters prescribed by the Companies Act 2014 are unmodified

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by Sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities and restrictions on use

Responsibilities of directors for the financial statements

As explained more fully in the directors' responsibilities statement set out on page 6, the directors are responsible for: the preparation of the financial statements including being satisfied that they give a true and fair view; such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.



Independent auditor's report to the members of LGC Science Ireland Limited
(continued)

Respective responsibilities and restrictions on use (continued)

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A fuller description of our responsibilities is provided on IAASA's website at <https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements/>.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the Company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Brian MacSweeney

20 January 2026

Brian MacSweeney
for and on behalf of
KPMG
Chartered Accountants, Statutory Audit Firm
85 South Mall
Cork
T12 A3XN

LGC Science Ireland Limited

**Profit and Loss Account and Other Comprehensive Income
 for the Year Ended 31 March 2025**

	Note	2025	2024
Administrative expenses		€ (123,188)	€ (68,000)
Operating loss - continuing operations		(123,188)	(68,000)
Interest receivable and other similar income	4	9,716,379	10,518,914
Interest payable and similar charges	5	(9,723,738)	(9,404,292)
Impairment of investment in subsidiary		(4,367,945)	
Profit on ordinary activities before taxation	3	(4,498,492)	1,046,622
Tax on profit/(loss) on ordinary activities	6	-	-
Profit/(loss) retained for the financial year		(4,498,492)	1,046,622
Other comprehensive income		-	8,803
Total comprehensive income/(loss) for the financial year		(4,498,492)	1,055,425

All amounts above relate to continuing operations.

There is no other comprehensive income in the year and the prior period other than the result recorded in Profit and Loss Account and Other Comprehensive Income.

The notes on pages 13 to 19 form part of these financial statements.

LGC Science Ireland Limited

Statement of Changes in Equity as at 31 March 2025

	Called up share capital	Profit and loss account	Total equity
	€	€	€
At 1 April 2023	84,337,034	(3,613,714)	80,723,320
Profit for the year	-	1,055,425	1,055,425
At 1 April 2024	84,337,034	(2,558,289)	81,778,745
Loss for the year	-	(4,498,492)	(4,498,492)
At 31 March 2025	84,337,034	(7,056,781)	77,280,253

LGC Science Ireland Limited

Balance Sheet as at 31 March 2025


	Note	2025 €	2024 €
Fixed assets			
Financial fixed assets	7	171,589,793	175,957,738
		<u>171,589,793</u>	<u>175,957,738</u>
Current assets			
Debtors	8	4,463,796	10,473,843
Creditors: amounts falling due within one year	9	(1,470,771)	(805,985)
Net current assets (liabilities)		<u>2,993,025</u>	<u>9,667,858</u>
Total assets less current liabilities		<u>174,582,818</u>	<u>185,625,596</u>
Creditors: amounts falling due after more than one year	10	(97,302,566)	(103,846,851)
Net assets		<u>77,280,253</u>	<u>81,778,745</u>
Capital and reserves			
Called up share capital	11	84,337,034	84,337,034
Profit and loss account		(7,056,781)	(2,558,289)
Shareholders' funds		<u>77,280,253</u>	<u>81,778,745</u>

The financial statements were approved and authorised for issue by the board:

On behalf of the board

Signed by:

 F859F0B68D50462.....
Donal Tabb

DocuSigned by:

 E6DPB12A4E9B484:.....
Lucas-Caspar Schwinner-Strachwitz

Date: 18 December 2025

Date: 18 December 2025

The notes on pages 12 to 18 form part of these financial statements.

LGC Science Ireland Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

1. General information

These financial statements comprising the Profit and Loss Account and Other Comprehensive Income, the Statement of Changes in Equity, the Balance Sheet and the related notes constitute the financial statements of LGC Science Ireland Limited for the financial year ended 31 March 2025.

LGC Science Ireland Limited is a limited liability company incorporated in Ireland with a registered number of 668590. The Registered Office is 6th Floor, 2 Grand Canal Square, Dublin 2, Dublin, Ireland.

2. Accounting policies

2.1. Statement of compliance

These financial statements have been prepared in compliance with applicable standards issued by the Financial Reporting Council, specifically FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland.

The presentation currency of these financial statements and the functional currency of the Company is Euro.

The Company's ultimate holding undertaking, LGC Science Corporation Limited includes the Company in its consolidated financial statements. The consolidated financial statements of LGC Science Corporation Limited are prepared in accordance with International Financial Reporting Standards as adopted by the EU and are available to the public and may be obtained from 10 The Priestly Centre, Priestly Road, Guildford, Surrey.

In these financial statements, the Company is considered to be a qualifying entity (for the purposes of this FRS) and has applied the exemptions available under FRS 102 in respect of the following disclosures:

- Reconciliation of the number of shares outstanding from the beginning to end of the period required by FRS 102.4 Statement of Financial Position;
- Cash Flow Statement and related notes;

As the consolidated financial statements of LGC Science Corporation Limited include the equivalent disclosures, the company has also taken the exemptions under FRS 102 available in respect of the following disclosures:

- The disclosure required by FRS 102.11 Basic Financial Instruments; and FRS 102.12 Other Financial Instrument Issues in respect of financial instruments not falling within the fair value accounting rules of Schedule 3, paragraph 38 of the Companies Act 2014, and
- Certain disclosures required by FRS 102.29 Income Tax in respect of the Pillar Two model rules.

The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements.

Judgements made by the directors, in the application of these accounting policies that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in note 15.

2.2. Going concern

The Company's business activities, together with the factors likely to affect its future development, its financial position, and the principal risks and uncertainties likely to impact the Company are set out

LGC Science Ireland Limited

above.

The Company has net current assets of €2.9 million (2024: €9.7 million net assets) and net assets of €77.2 million (2024: €81.8 million) at 31 March 2025. The directors are satisfied that the Company has sufficient funding to meet any short-term obligations which may arise during the period of 12 months from the date of approval of the financial statements. The Company has obtained a letter of support from LGC Science Group Holdings Limited, the Company's intermediate parent company. The directors have confirmed the ability of LGC Science Group Holdings Limited to provide this support.

Accordingly, the directors have determined that it is appropriate, based on the above facts and circumstances, to adopt the going concern basis of accounting in preparing these financial statements.

2.3. Foreign currency

The Company's functional currency is Euro. Transactions in foreign currencies are translated to the functional currency at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are retranslated to the functional currency at foreign exchange rates ruling at the dates the fair value was determined. Foreign exchange differences arising on translation are recognised in the income statement (except for differences arising on the retranslation of qualifying cash flow hedges and items which are fair valued with changes taken to other comprehensive income, which are recognised in other comprehensive income).

2.4. Taxation

Current taxation represents the amount expected to be paid or recovered in respect of taxable profit for the year and is calculated using the tax rates and laws that have been enacted or substantively enacted at the balance sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more, or a right to pay less, tax in the future have occurred at the balance sheet date.

Timing differences are differences between profit as computed for taxation purposes and profit as stated in the financial statements which arise because certain items of income and expenditure in the financial statements are dealt with in different periods for taxation purposes.

Deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax is measured on a non-discounted basis at the tax rates that are expected to apply in the periods in which timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date.

2.5. Financial assets

Investments in subsidiaries are carried at cost less any provisions for impairment. The carrying values of investments are reviewed for impairment in periods where events or changes in circumstances indicate the carrying value may not be recoverable.

LGC Science Ireland Limited

2.6. Interest payable

Interest payable includes interest payable on loans from group undertakings. Interest is recognised in profit or loss as it accrues, using the effective interest method.

2.7. Short-term debtors and creditors

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the Profit and Loss Account and Other Comprehensive Income in other operating expenses.

2.8. Provisions

A provision is recognised in the balance sheet when the Company has a present legal or constructive obligation as a result of a past event, that can be reliably measured and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

3. Profit on ordinary activities before taxation

No remuneration has been paid by the Company to its directors. The Company did not have any employees in the current or prior year. Auditor's fees have been discharged by its subsidiary company, Technopath Clinical Diagnostics Holdings Limited.

4. Interest receivable and other similar income

	2025 €	2024 €
Other income	9,716,379	10,518,914

Other income relates to amounts received from a group company as payment for group relief surrendered to it by the LGC Science Ireland Limited.

5. Interest payable and similar expenses

	2025 €	2024 €
Interest payable to parent company (Note 9)	9,723,739	9,404,292

LGC Science Ireland Limited

6. Tax on profit on ordinary activities

(a) Analysis of Income Statement

	2025	2024
	€	€
Current tax:	-	-
Corporation tax at 12.5%	-	-
Total current tax	-	-
Deferred tax	-	-
Origination and reversal of timing differences	-	-
Total deferred tax	-	-
Tax on profit/(loss) on ordinary activities	-	-

(b) Reconciliation of the expected tax charge at the standard tax rate to the actual tax charge at the effective tax rate:

	2025	2024
	€	€
Profit/(loss) on ordinary activities before tax	(4,498,492)	1,046,622
Profit/(loss) on ordinary activities multiplied by standard rate of corporation tax in Ireland of 12.5% (2024 - 12.5%)	(562,311)	130,828
Non-taxable intra-group income	(562,311)	(1,314,864)
Non-deductible interest	-	1,175,536
Expenses of management surrendered	-	8,500
Total tax charge for the year	-	-

7. Financial fixed assets

	2025	2024
	€	€
Cost		
At 1 April 2024	175,957,738	175,957,738
Impairment	(4,367,945)	
Reduction in deferred consideration (Note 9)	-	
At 31 March 2025	171,589,793	175,957,738

The Company recognized an impairment on its investment in Innovapeak Limited to bring the cost to net realizable value (Note 14).

LGC Science Ireland Limited

7. Financial fixed assets (Continued)

On 17 December 2020, the Company acquired 100% of Innovapeak Limited for a total consideration of €14,682,641. This included a retention consideration of €1,762,381 which relates to future services which are recognised as an increase in the carrying value of investments over time €Nil (2024: €Nil) of these services were incurred during the year ended 31 March 2025.

On 15 December 2021, the Company contributed €1,538,050 to Innovapeak Limited as an irrevocable capital contribution.

The Company recognized an impairment on its investment in Innovapeak Limited to bring the cost to net realizable value (Note 14).

On 26 January 2021, the Company acquired 100% of Technopath Clinical Diagnostics Holdings Limited (TCDHL) for consideration of €141,542,500. This included a retention consideration of €15,025,320 which relates to future services which are recognised as an increase in the carrying value of investments over time €Nil (2024: €Nil) of these services were incurred during the year ended 31 March 2025.

On 23 April 2021, the Company contributed €26,033,241 to Technopath Clinical Diagnostics Holdings Limited ("TCDHL") as an irrevocable capital contribution.

The Company has taken advantage of the exemption in Section 315 of the Companies Act 2014 not to disclose the net assets and profit/loss of its subsidiary companies in which it holds more than 20%.

Details of the investments as at 31 March 2025 and 2024 are as follows

Name of subsidiary	Principal activity	Country of incorporation and principal place of business	Proportion of ownership interest and voting right held	Registered office
Innovapeak Limited	Software development	Republic of Ireland	100%	6th Floor, 2 Grand Canal Square Dublin 2
Technopath Clinical Diagnostics Holdings Limited	Life sciences	Republic of Ireland	100%	Technopath Life Science Park Fort Henry, Ballina Co. Tipperary

8. Debtors

	Notes	2025	2024
Intercompany receivables	(a)	4,463,796	10,473,843

LGC Science Ireland Limited

(a) Intercompany receivables are non-interest bearing and repayable on demand.

9. Creditors: Amounts falling due within one year

	2025	2024
Amounts due to parent company	1,235,825	744,246
Accruals	234,946	61,739
		-
	1,470,771	805,985

10. Creditors: Amounts falling due after more than one year

	2025	2024
Amounts owed to group undertakings		
Balance at beginning of the year	103,846,851	93,336,423
Payments made during the year	(15,573,106)	
Additions during the year	9,028,821	10,510,428
	97,302,566	103,846,851

The amounts disclosed as falling due after more than one year are in respect of amounts advanced to the Company by its immediate parent, LGC (Holdings) Limited.

The Company entered into various loan agreements with LGC (Holdings) Limited, as follows:

Commencement Date	Principal Amount	Fixed Repayment Date
17 December 2020	€6,958,310	17 December 2030
25 January 2021	€65,000,000	25 January 2031
31 March 2021	€3,110,382	31 March 2031
31 August 2021	€1,470,978	31 August 2031
31 January 2022	€15,916,596	31 January 2032
09 January 2023	€880,158	09 January 2033
28 March 2024	€10,510,428	28 March 2034
31 March 2025	€9,028,821	31 March 2035

Interest on each of the above loan agreements is charged at 6.3% above Euribor, which is included in the carrying value.

The Company also issued a funding bond to LGC (Holdings) Limited on 31 March 2025.

11. Called up share capital

	2025	2024
Allotted, called up and fully paid		
84,337,034 (2022 - 84,337,034) ordinary shares of €1.00 each	84,337,034	84,337,034

LGC Science Ireland Limited

12. Parent undertaking, controlling parties and related party transactions

The parent undertaking of the smallest and largest group of which the Company is a member and for which group financial statements are prepared is LGC Science Corporation Limited. The group financial statements of LGC Science Corporation Limited are available from 10 The Priestley Centre Priestley Road, 10 Priestley Road, Guildford, Surrey, GU2 7XY

The Company's ultimate parent company and controlling party is LGC Science Corporation S.a.r.l., a company incorporated in Luxembourg.

The Company's immediate holding company and controlling party is LGC (Holdings) Limited, a company incorporated in the United Kingdom with registered offices at Queens Road, Teddington, Middlesex, United Kingdom, TW11 OLY.

13. Related party transactions

The Company has availed of the exemption provided in FRS 102 Section 33.1A 'Related Party Disclosures' for wholly subsidiary undertakings whose voting rights are controlled within the group, from the requirements to give details of transactions with entities that are part of the group or investees of the group qualifying as related parties.

14. Post balance sheet events

LGC Science Ireland disposed of its share in Innovapeak Limited in July 2025. The agreed sale price was a reduction in the prior value of the investment and this impairment is reflected in this set of accounts for year ended 31st March 2025.

15. Key judgements and assumptions

In preparing the financial statements, management has made judgements, estimates and assumptions that affect the application accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

16. Approval of financial statements

The financial statements of LGC Science Ireland Limited were approved and authorised for issue by the Board of Directors on 18 December 2025